ASH: Legend patient-reported outcome data from Phase 3 CARTITUDE-4 study

 

• In CARTITUDE-4, CARVYKTI® demonstrated clinically meaningful improvements in patient-reported outcomes when compared to standard of care
• The as-treated population in CARTITUDE-4 demonstrated strong rates of progression-free survival and overall response
• Longer-term data from CARTITUDE-2 showed deep and durable responses in earlier lines of treatment among patients in Cohort A and Cohort B

https://www.biospace.com/article/releases/patient-reported-outcomes-from-the-cartitude-4-study-showed-clinically-meaningful-improvements-in-health-related-quality-of-life-and-reductions-in-multiple-myeloma-symptoms-following-treatment-with-carvykti-ciltacabtagene-autoleucel-/